A review of bevacizumab in the treatment of malignant pleural mesothelioma

被引：15

作者：

Brosseau, Solenn ^{[1
,2
,3
]}

Assoun, Sandra ^{[1
,2
]}

Naltet, Charles ^{[1
,2
]}

Steinmetz, Christelle ^{[4
]}

Gounant, Valerie ^{[1
,2
]}

Zalcman, Gerard ^{[1
,2
,3
]}

机构：

[1] Bichat Claude Bernard Hosp, AP HP, Dept Thorac Oncol, Paris, France

[2] Bichat Claude Bernard Hosp, AP HP, CIC 1425, Paris Nord CLIP2, Paris, France

[3] Univ Paris Diderot, Paris, France

[4] Bichat Claude Bernard Hosp, AP HP, Pharm Dept, 46 Rue Henri Huchard, F-75877 Paris 18, France

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 28期

关键词：

angiogenesis inhibitor; bevacizumab; malignant pleural mesothelioma; ENDOTHELIAL GROWTH-FACTOR; STAGING PROJECT PROPOSALS; FORTHCOMING 8TH EDITION; PHASE-II TRIAL; TNM CLASSIFICATION; IASLC MESOTHELIOMA; PLUS BEVACIZUMAB; CANCER-PATIENTS; PROGNOSTIC-FACTORS; OPEN-LABEL;

D O I：

10.2217/fon-2017-0307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for themajority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.

引用

页码：2537 / 2546

页数：10

共 57 条

[1] A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes [J].

Buikhuisen, Wieneke A. ;

Scharpfenecker, Marion ;

Griffioen, Arjan W. ;

Korse, Catharina M. ;

van Tinteren, Harm ;

Baas, Paul .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) :758-768

[2] Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study [J].

Buikhuisen, Wieneke A. ;

Burgers, Jacobus A. ;

Vincent, Andrew D. ;

Korse, Catharina M. ;

van Klaveren, Rob J. ;

Schramel, Franz M. N. H. ;

Pavlakis, Nick ;

Nowak, Anna K. ;

Custers, Frank L. J. ;

Schouwink, J. Hugo ;

Gans, Steven J. M. ;

Groen, Harry J. M. ;

Strankinga, Wim F. M. ;

Baas, Paul .

LANCET ONCOLOGY, 2013, 14 (06) :543-551

[3] Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium [J].

Campbell, Nicholas P. ;

Kunnavakkam, Rangesh ;

Leighl, Natasha ;

Vincent, Mark D. ;

Gandara, David R. ;

Koczywas, Marianna ;

Gitlitz, Barbara J. ;

Agamah, Edem ;

Thomas, Sachdev P. ;

Stadler, Walter M. ;

Vokes, Everett E. ;

Kindler, Hedy L. .

LUNG CANCER, 2012, 78 (01) :76-80

[4] Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM) [J].

Castagneto, B. ;

Botta, M. ;

Aitini, E. ;

Spigno, F. ;

Degiovanni, D. ;

Alabiso, O. ;

Serra, M. ;

Muzio, A. ;

Carbone, R. ;

Buosi, R. ;

Galbusera, V. ;

Piccolini, E. ;

Giaretto, L. ;

Rebella, L. ;

Mencoboni, M. .

ANNALS OF ONCOLOGY, 2008, 19 (02) :370-373

[5]

Centers for Disease Control and Prevention. United States cancer statistics, 1999 2013 CANC INC M

[6] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma [J].

Ceresoli, G. L. ;

Zucali, P. A. ;

Mencoboni, M. ;

Botta, M. ;

Grossi, F. ;

Cortinovis, D. ;

Zilembo, N. ;

Ripa, C. ;

Tiseo, M. ;

Favaretto, A. G. ;

Soto-Parra, H. ;

De Vincenzo, F. ;

Bruzzone, A. ;

Lorenzi, E. ;

Gianoncelli, L. ;

Ercoli, B. ;

Giordano, L. ;

Santoro, A. .

BRITISH JOURNAL OF CANCER, 2013, 109 (03) :552-558

[7] Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma [J].

Ceresoli, GL ;

Zucali, PA ;

Favaretto, AG ;

Grossi, F ;

Bidoli, P ;

Del Conte, G ;

Ceribelli, A ;

Bearz, A ;

Morenghi, E ;

Cavina, R ;

Marangolo, M ;

Parra, HJS ;

Santoro, A .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1443-1448

[8] Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition [J].

de Reynies, Aurelien ;

Jaurand, Marie-Claude ;

Renier, Annie ;

Couchy, Gabrielle ;

Hysi, Ilir ;

Elarouci, Nabila ;

Galateau-Salle, Francoise ;

Copin, Marie-Christine ;

Hofman, Paul ;

Cazes, Aurelie ;

Andujar, Pascal ;

Imbeaud, Sandrine ;

Petel, Fabien ;

Pairon, Jean-Claude ;

Le Pimpec-Barthes, Francoise ;

Zucman-Rossi, Jessica ;

Jean, Didier .

CLINICAL CANCER RESEARCH, 2014, 20 (05) :1323-1334

[9] Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma [J].

Demirag, F ;

Ünsal, E ;

Yilmaz, A ;

Çaglar, A .

CHEST, 2005, 128 (05) :3382-3387

[10] A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma [J].

Dowell, Jonathan E. ;

Dunphy, Frank R. ;

Taub, Robert N. ;

Gerber, David E. ;

Ngov, Likheng ;

Yan, Jingsheng ;

Xie, Yang ;

Kindler, Hedy Lee .

LUNG CANCER, 2012, 77 (03) :567-571

← 1 2 3 4 5 6 →